Dose Escalation Study Using Ultra-Hypofractionated, Image-Guided, Intensity-Modulated Radiotherapy in Prostate Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
Prostate CancerAdenocarcinoma
Interventions
RADIATION

Hypofractionated, image-guided, intensity-modulated external beam radiation

A standard dose escalation design is utilized, with the initial treatment assigned as 6.5 Gy/fraction for five fractions to a total dose of 32.5 Gy. For any given dose tier, an initial cohort of 30 patients will be treated. However to adjust for potentially inevaluable patients who dropout prior to a full toxicity collection to assess potential DLTs enrollment of up to five additional patients per cohort can occur, per PI's discretion. Dose escalation will proceed if \< 10% of the 30 patients treated per tier exhibit any dose limiting toxicity (DLT) once the entire tier cohort has a minimum follow-up of 3 months and half the tier cohort has a minimum follow-up of 6 months. Dose escalation to the next tier will occur by increasing the dose per fraction by 0.5 Gy while keeping the fraction number constant at 5, leading to a total dose increase of 2.5 Gy per dose tier.

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center, New York

10467

Montefiore Medical Center, The Bronx

10604

Memorial Sloan Kettering West Harrison, Harrison

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Cancer Center @ Suffolk, Commack

Unknown

Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre

Memorial Sloan Kettering Cancer Center@Phelps, Sleepy Hollow

All Listed Sponsors
collaborator

Montefiore Medical Center

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER